Oncology

Back to articles

Study, guidelines shed new light on lung cancer treatment

KEY POINT

Crizotinib (Xalkori—Pfizer) prolonged progression-free survival and increased response rates, as compared with standard chemotherapy, in patients with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non–small-cell lung cancer. Updated guidelines for the diagnosis and management of lung cancer were recently released from the American College of Chest Physicians.

SOURCES

Shaw AT et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94.